𝔖 Bobbio Scriptorium

✦ LIBER ✦

Increased Ability to Transplant and Improved Survival in Patients with High Risk Acute Myeloid Leukemia (AML) After Induction with High Dose Cytarabine and Mitoxantrone (HIDAC/MITO)

✍ Scribed by M. Ramanathan; J. Cerny; G. Raffel; L. Petrillo-Deluca; N. Tarrasky; R. Nath

Book ID: 116283315
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 68 KB
Volume: 18
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2011.12.511

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose busulfan, cyclophosphamide, an

High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia

✍ Farag, S S; Bolwell, B J; Elder, P J; Kalaycio, M; Lin, T; Pohlman, B; Penza, S; 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 191 KB

Is there a plateau in the survival curve

Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience

✍ Siddhartha Ganguly; Jaswinder Singh; Clint L. Divine; Delva Deauna-Limayo; David 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 320 KB

High dose therapy and autologous stem ce

High dose therapy and autologous stem cell transplant does not improve survival compared with continued combination chemotherapy in people at high risk of relapse after initial treatment of advanced Hodgkin’s lymphoma: Abstracted from: Federico M, Bellei M, Brice P et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy. Journal of Clinical Oncology 2003; 21: 2320–2325

📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 83 KB